Can Fite Biopharma Ltd
CANF
View Detailed Chart
0.212USD
+0.032+17.47%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
840.30MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+17.47%
5 Days
-15.99%
1 Month
-36.96%
6 Months
-79.63%
Year to Date
-86.97%
1 Year
-86.59%
View Detailed Chart
TradingKey Stock Score of Can Fite Biopharma Ltd
Currency: USD Updated: 2025-12-26Key Insights
Can Fite Biopharma Ltd's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 110/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Can Fite Biopharma Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
3
analysts
Buy
Current Rating
6.000
Target Price
+1734.86%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Can Fite Biopharma Ltd Highlights
StrengthsRisks
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Growing
The company is in a growing phase, with the latest annual income totaling USD 674.00K.
Overvalued
The company’s latest PE is -0.25, at a high 3-year percentile range.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.49.
Can Fite Biopharma Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Can Fite Biopharma Ltd Info
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Ticker SymbolCANF
CompanyCan Fite Biopharma Ltd
CEOFishman (Pnina)
Websitehttps://www.canfite.com/
FAQs
What is the current price of Can Fite Biopharma Ltd (CANF)?
The current price of Can Fite Biopharma Ltd (CANF) is 0.212.
What is the symbol of Can Fite Biopharma Ltd?
The ticker symbol of Can Fite Biopharma Ltd is CANF.
What is the 52-week high of Can Fite Biopharma Ltd?
The 52-week high of Can Fite Biopharma Ltd is 2.330.
What is the 52-week low of Can Fite Biopharma Ltd?
The 52-week low of Can Fite Biopharma Ltd is 0.170.
What is the market capitalization of Can Fite Biopharma Ltd?
The market capitalization of Can Fite Biopharma Ltd is 840.30M.
What is the net income of Can Fite Biopharma Ltd?
The net income of Can Fite Biopharma Ltd is -7.88M.
Is Can Fite Biopharma Ltd (CANF) currently rated as Buy, Hold, or Sell?
According to analysts, Can Fite Biopharma Ltd (CANF) has an overall rating of Buy, with a price target of 6.000.
What is the Earnings Per Share (EPS TTM) of Can Fite Biopharma Ltd (CANF)?
The Earnings Per Share (EPS TTM) of Can Fite Biopharma Ltd (CANF) is -0.864.
Related Instruments
+0.05%
-0.07%
+0.08%
+0.49%
+0.23%
+0.38%
-0.31%
-0.30%
-0.77%
+0.30%
+0.23%
-0.02%
-0.07%
+0.24%
+0.26%
+0.30%
+0.16%
0.00%
+0.58%
-0.02%Popular Symbols
